Haplotype Association of the MAP2K5 Gene with Antipsychotics-Induced Symptoms of Restless Legs Syndrome among Patients with Schizophrenia
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective Restless legs syndrome (RLS) is considered a genetic disease and, following a genome-wide association study conducted in 2007, the mitogen-activated protein kinase 5 (MAP2K5) gene has been regarded as the promising candidate gene for RLS. The present study investigated whether polymorphisms of MAP2K5 are associated with antipsychotics-induced RLS in schizophrenia. Methods We assessed antipsychotics-induced RLS symptoms in 190 Korean schizophrenic patients using the diagnostic criteria of the International Restless Legs Syndrome Study Group. Five single-nucleotide polymorphisms (SNPs) of MAP2K5 were genotyped. We investigated genetic and haplotypic associations of these five SNPs with the risk of antipsychotics-induced RLS symptoms. Results We divided the 190 subjects into 2 groups: 1) those with RLS symptoms (n=96) and 2) those without RLS symptoms (n=94). There were no significant intergroup differences in the distributions of the genotypes and alleles of the rs1026732, rs11635424, rs12593813, rs4489954, and rs3784709 SNPs. However, the haplotype analysis showed that the G-G-G-G-T (rs1026732-rs11635424-rs12593813-rs4489954-rs3784709) haplotype was associated with RLS symptoms (permutation p=0.033). Conclusion These data suggest that a haplotype of MAP2K5 polymorphisms confers increased susceptibility to antipsychotics-induced RLS symptoms in schizophrenic patients.
Abstract
Objective Restless legs syndrome (RLS) is considered a genetic disease and, following a genome-wide association study conducted in 2007, the mitogen-activated protein kinase 5 (MAP2K5) gene has been regarded as the promising candidate gene for RLS. The present study investigated whether polymorphisms of MAP2K5 are associated with antipsychotics-induced RLS in schizophrenia. Methods We assessed antipsychotics-induced RLS symptoms in 190 Korean schizophrenic patients using the diagnostic criteria of the International Restless Legs Syndrome Study Group. Five single-nucleotide polymorphisms (SNPs) of MAP2K5 were genotyped. We investigated genetic and haplotypic associations of these five SNPs with the risk of antipsychotics-induced RLS symptoms. Results We divided the 190 subjects into 2 groups: 1) those with RLS symptoms (n=96) and 2) those without RLS symptoms (n=94). There were no significant intergroup differences in the distributions of the genotypes and alleles of the rs1026732, rs11635424, rs12593813, rs4489954, and rs3784709 SNPs. However, the haplotype analysis showed that the G-G-G-G-T (rs1026732-rs11635424-rs12593813-rs4489954-rs3784709) haplotype was associated with RLS symptoms (permutation p=0.033). Conclusion These data suggest that a haplotype of MAP2K5 polymorphisms confers increased susceptibility to antipsychotics-induced RLS symptoms in schizophrenic patients.
참고문헌 (43)
- Phillips B, "Epidemiology of restless legs symptoms in adults", Arch Intern Med, 160, pp.2137~2141 (2000)[DOI]
- Oka Y, "Secondary restless legs syndrome", Brain Nerve, 61, pp.539~547 (2009)
- Kang SG, "Characteristics and clinical correlates of restless legs syndrome in schizophrenia", Prog Neuropsychopharmacol Biol Psychiatry, 31, pp.1078~1083 (2007)[DOI]
- Aggarwal S, "Restless leg syndrome associated with atypical antipsychotics: current status, pathophysiology, and clinical implications", Curr Drug Saf, 10, pp.98~105 (2015)[DOI]
- Winkelman JW, "Foundations of Psychiatric Sleep Medicine" (2010), Cambridge University Press
- Pichler I, "Linkage analysis identifies a novel locus for restless legs syndrome on chromosome 2q in a South Tyrolean population isolate", Am J Hum Genet, 79, pp.716~723 (2006)[DOI]
- Chen S, "Genomewide linkage scan identifies a novel susceptibility locus for RLS on chromosome 9p", Am J Hum Genet, 74, pp.876~885 (2004)[DOI]
- Desautels A, "Restless legs syndrome: confirmation of linkage to chromosome 12q, genetic heterogeneity, and evidence of complexity", Arch Neurol, 62, pp.591~596 (2005)[DOI]
- Levchenko A, "The 14q restless legs syndrome locus in the French Canadian population", Ann Neurol, 55, pp.887~891 (2004)[DOI]
- Kemlink D, "Suggestive evidence for linkage for restless legs syndrome on chromosome 19p13", Neurogenetics, 9, pp.75~82 (2008)[DOI]
- Levchenko A, "A novel autosomal dominant restless legs syndrome locus maps to chromosome 20p13", Neurology, 67, pp.900~901 (2006)[DOI]
- Levchenko A, "Autosomal-dominant locus for Restless Legs Syndrome in French- Canadians on chromosome 16p12.1", Mov Disord, 24, pp.40~50 (2009)[DOI]
- Stefansson H, "A genetic risk factor for periodic limb movements in sleep", N Engl J Med, 357, pp.639~647 (2007)[DOI]
- Winkelmann J, "Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions", Nat Genet, 39, pp.1000~1006 (2007)[DOI]
- Kang SG, "Possible association between G-protein <TEX>${\beta}3$<", TEX> subunit C825T polymorphism and antipsychotic-induced restless legs syndrome in schizophrenia, 2007, pp.19, 351~356
- Kang SG, "Association study between antipsychotics- induced restless legs syndrome and polymorphisms of dopamine D1, D2, D3, and D4 receptor genes in schizophrenia", Neuropsychobiology, 57, pp.49~54 (2008)[DOI]
- Kang SG, "Association study between antipsychotic-induced restless legs syndrome and polymorphisms of monoamine oxidase genes in schizophrenia", Hum Psychopharmacol, 25, pp.397~403 (2010)[DOI]
- 조철현, "Association between Antipsychotics-Induced Restless Legs Syndrome and Tyrosine Hydroxylase Gene Polymorphism", PSYCHIATRY INVESTIGATION, 6(3), pp.211~215 (2009), 대한신경정신의학회
- Kang SG, "The BTBD9 gene may be associated with antipsychotic-induced restless legs syndrome in schizophrenia", Hum Psychopharmacol, 28, pp.117~123 (2013)[DOI]
- Jung JS, "Association between restless legs syndrome and CLOCK and NPAS2 gene polymorphisms in schizophrenia", Chronobiol Int, 31, pp.838~844 (2014)[DOI]
- 강승걸, "MEIS1, a Promising Candidate Gene, Is Not Associated with the Core Symptoms of Antipsychotic-Induced Restless Legs Syndrome in Korean Schizophrenia Patients", PSYCHIATRY INVESTIGATION, 12(2), pp.263~267 (2015), 대한신경정신의학회[DOI]
- Han OS, "Structured Clinical Interview for DSM-IV Axis I Disorder-Korean Version" (2000), Hana Medical Publishing
- American Psychiatric Association, "Practice Guidelines for the Treatment of Patients with Schizophrenia" (1997), American Psychiatric Press
- Bazire S, "Psychotropic Drug Directory. The Professionals' Pocket Handbook and Aide Memoire" (2005), Fivepin
- Hales RE, "Textbook of Clinical Psychiatry, Fourth Ed." (2002), American Psychiatric Publishing
- Inagaki A, "Dose Equivalence of Psychotic Drugs" (1999), Seiwa Press
- Woods SW, "Chlorpromazine equivalent doses for the newer atypical antipsychotics", J Clin Psychiatry, 64, pp.663~667 (2003)[DOI]
- Allen RP, "Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless leg syndrome diagnosis and epidemiology workshop at the National Institute of Health", Sleep Med, 4, pp.101~119 (2003)[DOI]
- Walters AS, "Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome", Sleep Med, 4, pp.121~132 (2003)[DOI]
- Barnes TR, "A rating scale for drug-induced akathisia", Br J Psychiatry, pp.672~676 (1989)
- Lin CH, "Association of candidate genetic variants with restless legs syndrome in end stage renal disease: a multicenter case-control study in Taiwan", Eur J Neurol, 21, pp.492~498 (2014)[DOI]
- Klingaman EA, "Sleep disorders among people with schizophrenia: emerging research", Curr Psychiatry Rep, 17, pp.79~ (2015)[DOI]
- Kemlink D, "Replication of restless legs syndrome loci in three European populations", J Med Genet, 46, pp.315~318 (2009)[DOI]
- Moore H 4th, "Periodic leg movements during sleep are associated with polymorphisms in BTBD9, TOX3", BC034767, MEIS1, MAP2K5, Sleep, pp.2014, 37[DOI]
- Yang Q, "Association studies of variants in MEIS1, BTBD9, and MAP2K5", SKOR1 with restless legs syndrome in a US population, 2011, pp.12, 800~804
- Zhou G, "Components of a new human protein kinase signal transduction pathway", J Biol Chem, 270, pp.12665~12669 (1995)[DOI]
- Dinev D, "Extracellular signal regulated kinase 5 (ERK5) is required for the differentiation of muscle cells", EMBO Rep, 2, pp.829~834 (2001)[DOI]
- Cavanaugh JE, "Neuroprotective role of ERK1", 2 and ERK5 in a dopaminergic cell line under basal conditions and in response to oxidative stress, 2006, pp.84, 1367~1375
- Hening WA, "Current guidelines and standards of practice for restless legs syndrome", Am J Med, 120(1 Suppl 1), pp.S22~S27 (2007)[DOI]
- Mignot E, "A step forward for restless legs syndrome", Nat Genet, 39, pp.938~939 (2007)[DOI]
- Winkelmann J, "Genome-wide association study identifies novel restless legs syndrome susceptibility loci on 2p14 and 16q12.1", PLoS Genet, 7, pp.e1002171~ (2011)[DOI]
- Vilarino-Guell C, "A genetic risk factor for periodic limb movements in sleep", N Engl J Med, 358, pp.425~427 (2008)[DOI]
- Kim MK, "Association of restless legs syndrome variants in Korean patients with restless legs syndrome", Sleep, 36, pp.1787~1791 (2013)[DOI]
